Background:

Aripiprazole is a novel and atypical antipsychotic [1].

Aripiprazole has been found to be a dopamine-serotonin system stabilizer with potent partial agonist activity at dopamine D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. In addition, aripiprazole has been reported to label with the agonist [125I]7-OH-PIPAT and with the antagonist [3H]spiperone with 0.34±0.02nM and 0.70±0.22nM, respectively. Besides, aripiprazole has been revealed to dose-dependently and potently inhibit the increase in cAMP accumulation stimulated by forskolin in CHO cells and HEK-293 cells. Other results have also been reported that aripiprazole completely inhibited the increase GTPase activity stimulated by the D2 receptor agonist quinpirole in rat striatal membranes [1].

参考文献:
[1] Burris KD1, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul; 302(1):381-9.